Obviously, more case–control studies with specific populations of NAFLD-associated HCC are needed to validate whether circulating adiponectin is higher in patients with than without NAFLD-associated HCC. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.